Sign In
Buy PSTX
$9.50
+0 (+0%)
At Close: Apr 04, 2025
All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buy
01:32pm, Monday, 16'th Oct 2023
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
05:00pm, Tuesday, 03'rd Oct 2023
In the landscape of modern medicine, a trio of biotech giants may rewrite the rules of healthcare. In a world where precision and personalization have become the holy grail of treatment, these three c
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
06:56pm, Tuesday, 08'th Aug 2023
Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.69 per share a year ago.
What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock
01:41pm, Wednesday, 10'th May 2023
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates
08:37pm, Tuesday, 09'th May 2023
Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.93 per share a year ago.
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates
07:49pm, Thursday, 09'th Mar 2023
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for t
Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference
08:00am, Tuesday, 14'th Feb 2023
SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rar
Poseida Therapeutics: New Allogeneic Therapies, Leveraging Non-Viral Engineering
04:54pm, Monday, 06'th Feb 2023
Poseida Therapeutics, Inc. granted Takeda its worldwide license to gene-therapy technologies that included piggyBac, Cas-Clover, and biodegradable DNA/ RNA nanoparticle deliveries, including treatment
Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable
10:32am, Friday, 27'th Jan 2023
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that m
Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's Why
10:32am, Tuesday, 10'th Jan 2023
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that m
Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's Why
10:32am, Thursday, 15'th Dec 2022
Poseida Therapeutics, Inc. (PSTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (GVHD) or immune effector cell-associated neurotoxic
Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue Estimates
08:18pm, Thursday, 10'th Nov 2022
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 235.29% and 5,715.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead fo
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
02:06pm, Friday, 07'th Oct 2022
Best penny stocks to buy? Biotech penny stocks are heating up & these 4 might be worth watching now.
SAN DIEGO , Oct. 5, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create
